Joëlle Bigay

Joëlle Bigay

Auto-generated profile, based on publicly available information

Joëlle Bigay

UMR 7275, Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d’Azur, CNRS and Inserm, Sophia Antipolis, Valbonne, France

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Cell
Verified
Journal Article
Closed access
BMBruno Mesmin
Bruno Mesmin
JBJoëlle Bigay
Joëlle Bigay
JFJoachim Moser von Filseck
Joachim Moser von Filseck
SLSandra Lacas-Gervais
Sandra Lacas-Gervais
GDGuillaume Drin
Guillaume Drin
BABruno Antonny
Bruno Antonny


9 June 2005 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JBJoëlle Bigay
Joëlle Bigay
JCJean‐François Casella
Jean‐François Casella
GDGuillaume Drin
Guillaume Drin
BMBruno Mesmin
Bruno Mesmin
BABruno Antonny
Bruno Antonny
ArfGAP1 promotes GTP hydrolysis in Arf1, a small G protein that interacts with lipid membranes and drives the assembly of the COPI coat in a GTP‐dependent manner. The activity of ArfGAP1 increases with membrane curvature, suggesting a negative feedback loop in which COPI‐induced membrane deformation determines the timing and location of GTP hydrolysis within a coated bud. Here we show that a central sequence of about 40 amino acids in ArfGAP1 acts as a lipid‐packing sensor. This ALPS motif (ArfGAP1 Lipid Packing Sensor) is also found in the yeast homologue Gcs1p and is necessary for coupling ArfGAP1 activity with membrane curvature. The ALPS motif binds avidly to small liposomes and shows the same hypersensitivity on liposome radius as full‐length ArfGAP1. Site‐directed mutagenesis, limited proteolysis and circular dichroism experiments suggest that the ALPS motif, which is unstructured in solution, inserts bulky hydrophobic residues between loosely packed lipids and forms an amphipathic helix on highly curved membranes. This helix differs from classical amphipathic helices by the abundance of serine and threonine residues on its polar face.

28 October 1985 in FEBS Letters
Verified
Journal Article
Closed access
JBJoëlle Bigay
Joëlle Bigay
PDPhilippe Deterre
Philippe Deterre
CPClaude Pfister
Claude Pfister
MCMarc Chabre
Marc Chabre

1 December 2003 in Nature
Verified
Journal Article
Closed access
PDF file
JBJoëlle Bigay
Joëlle Bigay
PGPierre Gounon
Pierre Gounon
SRSylviane Robineau
Sylviane Robineau
BABruno Antonny
Bruno Antonny

1 February 2015 in Cell Reports
Verified
Journal Article
Open access
JSJeroen Strating
Jeroen Strating
LLLonneke van der Linden
Lonneke van der Linden
LALucian Albulescu
Lucian Albulescu
JBJoëlle Bigay
Joëlle Bigay
MAMinetaro Arita
Minetaro Arita
FKFrank Van Kuppeveld
Frank Van Kuppeveld
Itraconazole (ITZ) is a well-known antifungal agent that also has anticancer activity. In this study, we identify ITZ as a broad-spectrum inhibitor of enteroviruses (e.g., poliovirus, coxsackievirus, enterovirus-71, rhinovirus). We demonstrate that ITZ inhibits viral RNA replication by targeting oxysterol-binding protein (OSBP) and OSBP-related protein 4 (ORP4). Consistently, OSW-1, a specific OSBP/ORP4 antagonist, also inhibits enterovirus replication. Knockdown of OSBP inhibits virus replication, whereas overexpression of OSBP or ORP4 counteracts the antiviral effects of ITZ and OSW-1. ITZ binds OSBP and inhibits its function, i.e., shuttling of cholesterol and phosphatidylinositol-4-phosphate between membranes, thereby likely perturbing the virus-induced membrane alterations essential for viral replication organelle formation. ITZ also inhibits hepatitis C virus replication, which also relies on OSBP. Together, these data implicate OSBP/ORP4 as molecular targets of ITZ and point to an essential role of OSBP/ORP4-mediated lipid exchange in virus replication that can be targeted by antiviral drugs.